Citi initiated coverage of AstraZeneca (AZN) with a Buy rating and 17,000 GBp price target The firm says the company has the “fastest” mid-term sales and earning growth in the Europe pharma sector. This is driven by AstraZeneca’s in-market and pipeline products, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca Sharpens Andexanet Strategy With New Phase I Dosing Study
- AstraZeneca Halts Early Heart Drug Study: What It Means for AZN Investors
- TROPION-SWISH: New Phase IV Study Targets Side-Effect Risk in AstraZeneca and Daiichi Sankyo’s Dato-DXd
- AstraZeneca Tests Capivasertib in Liver-Impaired Patients: What Investors Should Watch
- AstraZeneca Ends Early-Stage Ceralasertib Combo Study: What Investors Should Know